Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe ...

The Food and Drug Administration has approved Zepbound to treat obstructive sleep apnea for people who are moderately or ...

Vivos Therapeutics, with its groundbreaking FDA-cleared treatments ... Dec. 16, 2024 /PRNewswire-PRWeb/ -- Pediatric Obstructive Sleep Apnea (OSA) is a silent health crisis affecting an estimated ...

Inc. today announced a strategic joint marketing venture aimed at providing comprehensive solutions for patients with obstructive sleep apnea (OSA) and associated oxidative stress. This collaboration ...

Nyxoah SA (NASDAQ:NYXH), a medical technology company specializing in the treatment of obstructive sleep apnea (OSA), has been ... focus for Nyxoah is obtaining FDA approval for the Genio system ...

Advertisement The FDA first announced two months ago that ... and Drug Administration for treating moderate to severe obstructive sleep apnea. Health News // 4 hours ago Missouri judge partially ...

This collaboration combines Vivos Therapeutics' FDA-cleared oral medical devices ... most important reversible risk factors for obstructive sleep apnea. Studies suggest that obesity is a major ...

Vivos Therapeutics brings hope to the 90 million Americans affected by obstructive sleep apnea (OSA). Their FDA-cleared Vivos CARE oral devices offer a non-invasive alternative to CPAP therapy ...